Avatrombopag

From WikiProjectMed
Jump to navigation Jump to search

Avatrombopag
Avatrombopag.svg
Names
Pronunciationa" va trom' boe pag
Trade namesDoptelet
Other namesAvatrombopag maleate
  • 1-[3-Chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid
Clinical data
Drug classThrombopoietin receptor agonist[1]
Main usesLow platelets in chronic liver disease[2][3]
Side effectsFever, abdominal pain, nausea, headache, tiredness, peripheral swelling[2]
Pregnancy
category
  • US: N (Not classified yet)
Routes of
use
By mouth
Typical dose40 to 60 mg OD[3]
External links
AHFS/Drugs.comMonograph
US NLMAvatrombopag
MedlinePlusa618032
Legal
License data
Legal status
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Chemical and physical data
FormulaC29H34Cl2N6O3S2
Molar mass649.65 g·mol−1
3D model (JSmol)
  • C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl
  • InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38) checkY
  • Key:OFZJKCQENFPZBH-UHFFFAOYSA-N

Avatrombopag, sold under the brand name Doptelet, is a medication used to treat low platelets in chronic liver disease when an invasive medical procedure is required.[2][3] It is taken by mouth.[1]

Common side effects include fever, abdominal pain, nausea, headache, tiredness, and peripheral swelling.[2] Other side effects may include blood clots.[2] Use in pregnancy may harm the baby.[2] Safety in pregnancy or breastfeeding is unclear.[1] It is a thrombopoietin receptor agonist, which increases platelet production.[1]

Avatrombopag was approved for medical use in the United States in 2018 and Europe in 2019.[2][3] In the United Kingdom a course of treatment costs the NHS £640 to £960 as of 2020.[4] In the United States this amount is 3,650 USD to 5,500 USD.[5]

Medical uses

Dosage

It should be started 10 days before the procedure.[3] It is used at a dose of 40 to 60 mg per day, depending on a persons platelets, for 5 days.[2]

References

  1. 1.0 1.1 1.2 1.3 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1079. ISBN 978-0857114105.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 "Avatrombopag Monograph for Professionals". Drugs.com. Archived from the original on 25 January 2021. Retrieved 16 January 2022.
  3. 3.0 3.1 3.2 3.3 3.4 "Doptelet EPAR". European Medicines Agency (EMA). 24 April 2019. Archived from the original on 22 May 2020. Retrieved 2 May 2020.
  4. "Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure". Archived from the original on 17 January 2022. Retrieved 16 January 2022.
  5. "Doptelet Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 April 2021. Retrieved 16 January 2022.

External links

External sites:
Identifiers: